August 11, 2016 09:40 AM EDT
R&D

The Brent Saun­ders way: Al­ler­gan pays $95M for its next step­ping stone to a big­ger pipeline

John Carroll

Editor & Founder

Al­ler­gan has picked up an­oth­er one of its “step­ping stone” ac­qui­si­tions. The deal-hun­gry com­pa­ny bagged For­Sight VI­SION5 and its glau­co­ma tech­nol­o­gy for a $95 mil­lion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

A service from the Financial Times